Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription 13.10.2025 1 Am J Hematol 4 Ann Hematol 5 Blood 1 BMC Cancer 1 BMC Genomics 1 Bone Marrow Transplant 20 Br J Haematol 5 Leuk Lymphoma 1 Leuk Res 4 Leukemia 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. PASVOLSKY O, Shimony S, Saliba RM, Marcoux C, et al
   Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia-A Retrospective, Dual-Center Study.
   Am J Hematol. 2025 Oct 6. doi: 10.1002/ajh.70101.
   PubMed         Abstract available
   
   

   
   Ann Hematol

2. DAI JT, He YY, Zhang YT, Zhang YJ, et al
   A multicenter study on the prognostic value of prednisone response in pediatric acute lymphoblastic leukemia.
   Ann Hematol. 2025 Oct 10. doi: 10.1007/s00277-025-06656.
   PubMed         Abstract available
   
   
3. ASHAYE A, Shi L, Aldoss I, Montesinos P, et al
   Impact of clinical response and treatment tolerability on HRQoL in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib.
   Ann Hematol. 2025 Oct 10. doi: 10.1007/s00277-025-06635.
   PubMed         Abstract available
   
   
4. SONG F, Su L, Gao S
   Impact of FLT3 mutation on its intracellular localization and implications for anti-leukemia strategy.
   Ann Hematol. 2025 Oct 9. doi: 10.1007/s00277-025-06671.
   PubMed         Abstract available
   
   
5. MAMLEKAR H, Gangadaran N, Yadav S, Kashyap R, et al
   Clinical profile and treatment outcomes in paediatric and adult acute promyelocytic leukemia: experience from a tertiary care centre in Northern India.
   Ann Hematol. 2025 Oct 7. doi: 10.1007/s00277-025-06646.
   PubMed         Abstract available
   
   

   
   Blood

6. OTHMAN J, Potter N, Freeman SD, McCarthy N, et al
   Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.
   Blood. 2025;146:1862-1867.
   PubMed         Abstract available
   
   
7. BROWN JR, Nguyen B, Desikan SP, Won H, et al
   Genomic Determinants of Response and Resistance to Pirtobrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia.
   Blood. 2025 Oct 7:blood.2024027009. doi: 10.1182/blood.2024027009.
   PubMed         Abstract available
   
   
8. SHI M, Rech KL
   T-large granular lymphocytic leukemia transformation to peripheral T-cell lymphoma.
   Blood. 2025;146:1868.
   PubMed        
   
   
9. PASTOORS D, Havermans M, Mulet-Lazaro R, Smeenk L, et al
   MECOM is a master repressor of myeloid differentiation through dose control of CEBPA in acute myeloid leukemia.
   Blood. 2025 Oct 8:blood.2025028914. doi: 10.1182/blood.2025028914.
   PubMed         Abstract available
   
   
10. SCHROEDER B, Yuan CM, Wang HW, Mohindroo C, et al
    Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia.
    Blood. 2025 Oct 8:blood.2025031243. doi: 10.1182/blood.2025031243.
    PubMed         Abstract available
    
    

    
    BMC Cancer

11. WANG YL, Chang TY, Chen SH, Hsiao YW, et al
    The relationship between urine output and time to methotrexate clearance in pediatric leukemia patients receiving high-dose methotrexate therapy.
    BMC Cancer. 2025;25:1545.
    PubMed         Abstract available
    
    

    
    BMC Genomics

12. PLUTA A, Droscha C
    Identification of novel RNA polymerase III promoters in bovine leukemia virus miRNA cluster by cross-taxa analysis of small non-coding RNAs.
    BMC Genomics. 2025;26:882.
    PubMed         Abstract available
    
    

    
    Bone Marrow Transplant

13. YANADA M, Yamasaki S, Mizuno S, Sugita J, et al
    Comparison of single-unit umbilical cord blood transplantation and haploidentical transplantation using posttransplant cyclophosphamide during first complete remission of acute myeloid leukemia.
    Bone Marrow Transplant. 2025 Oct 5. doi: 10.1038/s41409-025-02729.
    PubMed         Abstract available
    
    

    
    Br J Haematol

14. NIELSEN NN, Jensen JF, Ovlisen A, Zenas DR, et al
    Reproductive patterns and birth rates in acute leukaemia survivors: A Danish population-based cohort study.
    Br J Haematol. 2025;207:1435-1444.
    PubMed         Abstract available
    
    
15. JENSEN RH, Teglgaard C, Jensen JF, Baech J, et al
    Cardiotoxicity in patients with acute myeloid leukaemia following anthracycline-containing chemotherapy: A population-based matched cohort study.
    Br J Haematol. 2025;207:1416-1424.
    PubMed         Abstract available
    
    
16. DREYZIN A, Holtzman NG, Bonifant CL
    CD123-targeting immunotherapeutic approaches in acute myeloid leukaemia.
    Br J Haematol. 2025;207:1178-1191.
    PubMed         Abstract available
    
    
17. ANGOTZI F, Cellini A, Danesin N, Zoletto S, et al
    Serum soluble interleukin-2 receptor levels in hairy cell leukaemia as a marker of tumour burden with prognostic value and as a tool for disease monitoring.
    Br J Haematol. 2025;207:1357-1365.
    PubMed         Abstract available
    
    
18. SCHONUNG M, Rathmann S, Ramamoorthy S, Lebrecht D, et al
    Assessment of peripheral blood DNA methylation signatures as pharmacodynamic and predictive biomarkers during azacitidine therapy in juvenile myelomonocytic leukaemia: Results of the EWOG-MESRAT study.
    Br J Haematol. 2025;207:1271-1278.
    PubMed         Abstract available
    
    
19. DANYLESKO I, Shimoni A, Avigdor A, Kedmi M, et al
    Bisantrene in combination with fludarabine and clofarabine as salvage therapy for adult patients with refractory or relapsed acute myeloid leukaemia (AML)-An open-label, phase I/II study.
    Br J Haematol. 2025;207:1425-1434.
    PubMed         Abstract available
    
    
20. SKOPEK R, Ozcan SG, Chmiel P, Morgner S, et al
    Synergistic potential of CDK4/6 inhibitors and ATRA in non-APL AML.
    Br J Haematol. 2025;207:1279-1288.
    PubMed         Abstract available
    
    
21. MUNYURANGABO G, Zhang L, Zhou Y, Zhang P, et al
    Co-operative epigenetic remodelling by Setd2 deficiency and Kras mutation drives juvenile myelomonocytic leukaemia development and MEK inhibitor sensitivity.
    Br J Haematol. 2025;207:1289-1300.
    PubMed         Abstract available
    
    
22. HUANG N, Chang C, Wu L, He Q, et al
    Characteristics and prognostic implications of TP53 mutations in Chinese patients with myelodysplastic syndromes.
    Br J Haematol. 2025;207:1397-1407.
    PubMed         Abstract available
    
    
23. ZHONG M, Yin C, Wang Y, Zeng L, et al
    HOX11 gene overexpression is associated with recurrence of acute B lymphoblastic leukaemia.
    Br J Haematol. 2025;207:1301-1308.
    PubMed         Abstract available
    
    
24. LIU Y, Liu W, Mei Y, Huang Q, et al
    Single-cell transcriptome profiling reveals blast cell heterogeneity and identifies novel therapeutic target IKZF2 in t(8;21) acute myeloid leukaemia.
    Br J Haematol. 2025;207:1309-1322.
    PubMed         Abstract available
    
    
25. YUAN M, Zhang Y, Liu B, Zhou L, et al
    Treatment-free remission in chronic myeloid leukaemia patients with accelerated phase or tyrosine kinase inhibitor therapy failure.
    Br J Haematol. 2025;207:1408-1415.
    PubMed         Abstract available
    
    
26. TE VRUGT M, Newman H, Teachey DT, Burkhardt B, et al
    T-cell lymphoblastic lymphoma in children, adolescents and young adults.
    Br J Haematol. 2025 Aug 13. doi: 10.1111/bjh.70053.
    PubMed         Abstract available
    
    
27. SHI H, Shu W, Tao Y, Jia X, et al
    White blood cell count as a powerful prognostic marker and treatment guide in paediatric acute myeloid leukaemia with NUP98 rearrangement.
    Br J Haematol. 2025;207:1464-1475.
    PubMed         Abstract available
    
    
28. HERLIN MK, Kjeldsen E, Abrahamsson J, Arad-Cohen N, et al
    Characteristics and prognosis of paediatric normal karyotype acute myeloid leukaemia: A NOPHO-DBH AML study.
    Br J Haematol. 2025;207:1454-1463.
    PubMed         Abstract available
    
    
29. EGGER-HEIDRICH K, Sockel K, Schetelig J
    Back to life: Biological parenthood of young adult acute leukaemia survivors.
    Br J Haematol. 2025;207:1728-1730.
    PubMed         Abstract available
    
    
30. LIANG H, He B, Chen J, Luo B, et al
    Paediatric-inspired regimen reduces central nervous system relapse in adult acute lymphoblastic leukaemia.
    Br J Haematol. 2025;207:1445-1453.
    PubMed         Abstract available
    
    
31. SHARMA P, Leons GK, Singh V, Naseer S, et al
    Gene expression signature of IKZF1 deleted B-cell acute lymphoblastic leukaemia reveals a unique regulation of MUC4.
    Br J Haematol. 2025;207:1259-1270.
    PubMed         Abstract available
    
    
32. NACHMIAS B, Haran A, Yisraeli Salman M, Stein EM, et al
    Measurable residual disease-guided therapy in acute myeloid leukaemia: Practical insights.
    Br J Haematol. 2025;207:1192-1212.
    PubMed         Abstract available
    
    
33. POURHASSAN H, Tinajero J, Ma H, Jackson R, et al
    The efficacy of targeted and immune-based therapies in adults with TP53-mutated acute lymphoblastic leukaemia.
    Br J Haematol. 2025;207:1377-1387.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

34. HUANG YH, Liu FT, Wan CL, Wang ZJ, et al
    Venetoclax plus hypomethylating agents versus priming regimen as the first-line therapy for newly diagnosed acute myeloid leukemia with myelodysplasia-related changes: a propensity score-matched analysis.
    Leuk Lymphoma. 2025 Oct 6:1-11. doi: 10.1080/10428194.2025.2566317.
    PubMed         Abstract available
    
    
35. WATRIN T, Seifert M, Dietrich S
    The tumor microenvironment in hairy cell leukemia (HCL) and splenic B cell lymphoma with prominent nucleoli (SBLPN).
    Leuk Lymphoma. 2025 Oct 6:1-10. doi: 10.1080/10428194.2025.2562951.
    PubMed         Abstract available
    
    
36. TADMOR T, Demeter J, Fagarasanu A, Kreitman RJ, et al
    Expert consensus opinion on the management of hairy cell leukemia in elderly patients.
    Leuk Lymphoma. 2025 Oct 10:1-7. doi: 10.1080/10428194.2025.2562961.
    PubMed         Abstract available
    
    
37. PARK H, Lee JH, Lee JH, Park HS, et al
    Optimal conditioning intensity: favorable outcome of a 3-day busulfan based regimen in younger acute myeloid leukemia patients.
    Leuk Lymphoma. 2025 Oct 10:1-14. doi: 10.1080/10428194.2025.2560086.
    PubMed         Abstract available
    
    
38. MCCORMICK B, Findley A, Diebold K, Bourne G, et al
    Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2025 Oct 10:1-11. doi: 10.1080/10428194.2025.2564766.
    PubMed         Abstract available
    
    

    
    Leuk Res

39. WANG L, Kurt M, Disher T, Liu FF, et al
    Evaluating complete response/remission rate as a surrogate endpoint in relapsed/refractory chronic lymphocytic leukemia.
    Leuk Res. 2025;158:108113.
    PubMed         Abstract available
    
    

    
    Leukemia

40. GEELS J, van Rhenen A, Gradowska P, Asselbergs FW, et al
    Heart failure in patients with acute myeloid leukemia (AML) treated with anthracycline agents during remission induction therapy: a systematic review and meta-analysis.
    Leukemia. 2025 Oct 10. doi: 10.1038/s41375-025-02753.
    PubMed         Abstract available
    
    
41. VOSS RK, Pastor Loyola VB, Cardenas MF, Kumar P, et al
    Clinical experience of using integrated whole genome and transcriptome sequencing as a framework for pediatric and adolescent acute myeloid leukemia diagnosis and risk assessment.
    Leukemia. 2025 Oct 7. doi: 10.1038/s41375-025-02774.
    PubMed         Abstract available
    
    
42. HUND I, Hess ME, Andrieux G, Stomper J, et al
    Genetic and epigenetic alterations at secondary resistance after continued decitabine-based treatment of acute myeloid leukemia in the randomized phase II DECIDER trial.
    Leukemia. 2025 Oct 7. doi: 10.1038/s41375-025-02780.
    PubMed        
    
    
43. TAMAI H, Miyake K, Miyake N, Asano J, et al
    Combined treatment with amlexanox and cytarabine induces apoptosis via the S100A6-Akt pathway in KMT2A::AFF1-positive acute lymphoblastic leukemia.
    Leukemia. 2025 Oct 6. doi: 10.1038/s41375-025-02782.
    PubMed        
    
    

    
    PLoS One

44. CHEN B, Gao Z, Chen L, Zhang H, et al
    Detection of leukemia gene fusions on DNA-level through targeted Next-Generation Sequencing.
    PLoS One. 2025;20:e0332407.
    PubMed         Abstract available
    
    
45. YANG D, Li Y, Ma P, Xiao F, et al
    Integrated analysis of ARHGAP6 potential function and prognostic value in acute myeloid leukemia.
    PLoS One. 2025;20:e0333409.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.